A randomized, double-masked and cross-over dietary intervention study to investigate the effects of diet supplementation with cocoa flavanols on arterial stiffness in healthy adult human subjects.
Cocoa flavanols (CF) are plant-derived compounds commonly present in the human diet. Examples of flavanol-containing foods and beverages are apples, chocolate, tea, wine, berries, pomegranate and nuts. Flavanols encompass a group of different compounds, and the final profile of flavanols in foods will depend on multiple factors including plant origin, time of harvesting, storage, food processing, and cooking techniques. The term "cocoa flavanols" (CF) as used here refers to the particular profile of flavanols and procyanidins naturally found in cocoa beans, and CF mainly consist of the monomeric flavanol (-)-epicatechin and its oligomeric derivatives (procyanidins) containing up to 10 monomer subunits. Accumulating data resulting from dietary intervention studies suggest that the intake of diets rich in flavanols can exert a beneficial cardiovascular health effect in humans. However, most of these investigations have been conducted with patients with diverse health complications (e.g. hypertension, diabetes and coronary heart disease) rather than healthy subjects. Thus, the interpretation of these data in the context of nutrition, primary prevention, and dietary recommendations is limited. In the current study, the investigators propose to investigate the effects of cocoa flavanol intake on arterial stiffness in a healthy population of adults. The investigators submit that this investigation will provide novel insights into the potential health benefits of dietary flavanols and procyanidins in the context of cardiovascular health in humans. The data resulting from this study will be key to the design of larger scale studies in this context, which are needed to comprehensively study the role of dietary flavanols and procyanidins with regard to potential dietary recommendations and public health.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
10
Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
Ragle Human Nutrition Research Center, Department of Nutrition at UC Davis
Davis, California, United States
Individual changes in systolic blood pressure (in office)
assessed as systolic blood pressure
Time frame: Baseline and 2, 4, 6, 8 and 10 weeks following intervention
Individual changes in diastolic blood pressure (in office)
assessed as diastolic blood pressure
Time frame: Baseline and 2, 4, 6, 8 and 10 weeks following intervention
Individual changes in augmentation index (in office)
assessed as augmentation index
Time frame: Baseline and 2, 4, 6, 8 and 10 weeks following intervention
Individual changes in central blood pressure (in office)
assessed as central blood pressure
Time frame: Baseline and 2, 4, 6, 8 and 10 weeks following intervention
Individual changes in blood pressure (at home)
self monitoring blood pressure
Time frame: Daily for 2 weeks between 0, 2, 4, 6, 8 and 10 weeks of intervention
Individual changes in pulse wave velocity (in office)
assessed as pulse wave velocity
Time frame: Baseline and 2, 4, 6, 8 and 10 weeks following intervention
Individual changes in lipid profile
Total cholesterol, LDL, HDL and Triglycerides
Time frame: Baseline and 2, 4, 6, 8 and 10 weeks following intervention
Individual changes in flavanol metabolites in plasma and urine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
flavanol/methylxanthine metabolites in plasma and urine
Time frame: Baseline and 2, 4, 6, 8, 10 weeks following intervention
Individual changes in methylxanthine metabolites in plasma and urine
flavanol/methylxanthine metabolites in plasma and urine
Time frame: Baseline and 2, 4, 6, 8, 10 weeks following intervention
Individual changes in CMP
comprehensive metabolic panel
Time frame: Baseline and 2, 4, 6, 8, 10 weeks following intervention
Individual changes in Step test performance
Volunteers will be asked to step up and down on a platform (7 inches high) at a rate of 23 steps per minute for no more than 3 minutes. Blood pressure will be measured before and after the step test.
Time frame: Baseline and 2, 4, 6, 8, 10 weeks following intervention